🔗 Share this article

Given that America proceeds with sweeping revisions to its vaccine schedules, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccines throughout the global health crisis and has focused upon potential deaths following COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Schedule

Public health authorities were set to reveal sweeping changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with much of the global community with insufficient data for benefit. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a closer partnership between the drug and vaccine centers as Høeg and Prasad consolidate power at the agency – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US so as to align more like the Danish model, a nation with nationalized medicine and a population approximately the population of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no apparent background in medication creation, regulation or administrative roles, which has been customary for former leaders of the biologics center. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous heads of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who headed CBER have had.”

CDER has an immense portfolio at the FDA, she pointed out.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and each of these have to be supervised,” she said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership component to the position, which supervises more than 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” she concluded.

Official Statement and Disputed Programs

In response to questions about Høeg’s fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “questions are based on flawed presumptions”.

“Her experience matches the duties of her position,” the spokesperson explained, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a controversial one-day therapy clearance system that reportedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he said, “the FDA looks to be trending towards laxer rules of most medications, with the exception of shots.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, some experts have noted. She published a study using non-validated public submissions to estimate the incidence of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Among her “desired changes” for the current federal leadership featured changing guidelines for novel immunizations and ending “optional” immunizations, she said following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She is an thorough true believer who commences with her beliefs and tailors the evidence to accommodate the evidence in a highly disingenuous, untruthful fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|